FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894492020> ?p ?o ?g. }

• W2894492020 endingPage "45" @default.
• W2894492020 startingPage "42" @default.
• W2894492020 abstract "Objective: The activity of cabozantinib in nonclear cell histologies has not been evaluated. Materials and Methods: Data were collected across 24 Italian hospitals. Patients were aged 18 years and older with advanced nonclear cell renal cell carcinoma (RCC), with an Eastern Cooperative Oncology Group Performance Status 0 to 2, who had relapsed after previous systemic treatments for metastatic disease. Cabozantinib was administered orally at 60 mg once a day in 28 days cycles. Dose reductions to 40 or 20 mg were made due to toxicity. Adverse events (AEs) were monitored using CTCAE version 4.0. Results: Seventeen patients were enrolled. Three (18%) patients were diagnosed type I papillary RCC, 9 (53%) type II papillary, 3 (18%) chromophobe, and 2 (11%) with Bellini duct carcinoma. In total, 11 patients started with 60 mg. Six patients started a lower dose of 40 mg. Median progression-free survival was 7.83 months (0.4 to 13.4 mo), while median overall survival was not reached but 1-year overall survival was about 60%. Six patients (35%) experienced a partial response to treatment and 6 patients (35%) showed a stable disease. In the remaining 5 (30%), we observed a progressive disease. Grade 3 and 4 AEs were observed in 41% of patients. Among 20 patients, only 1 (6%) discontinued treatment due to AEs. Asthenia (41%), diarrhea (35%), aminotransferase increasing (35%), mucosal inflammation (35%), hand and foot syndrome (24%), and hypothyroidism (24%) were the most frequently AEs. Conclusions: Our data showed that, cabozantinib is a active and feasible treatment in patient with nonclear cell RCC." @default.
• W2894492020 created "2018-10-05" @default.
• W2894492020 creator A5005319110 @default.
• W2894492020 creator A5038576978 @default.
• W2894492020 creator A5040231574 @default.
• W2894492020 creator A5044033864 @default.
• W2894492020 creator A5053179795 @default.
• W2894492020 creator A5057926104 @default.
• W2894492020 creator A5063795761 @default.
• W2894492020 creator A5064767706 @default.
• W2894492020 creator A5065945024 @default.
• W2894492020 creator A5066976468 @default.
• W2894492020 creator A5071060598 @default.
• W2894492020 creator A5071208029 @default.
• W2894492020 creator A5071855568 @default.
• W2894492020 creator A5081355165 @default.
• W2894492020 creator A5088690292 @default.
• W2894492020 date "2019-01-01" @default.
• W2894492020 modified "2023-10-18" @default.
• W2894492020 title "Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma" @default.
• W2894492020 cites W1544119899 @default.
• W2894492020 cites W1965777729 @default.
• W2894492020 cites W2016079491 @default.
• W2894492020 cites W2019607817 @default.
• W2894492020 cites W2030116438 @default.
• W2894492020 cites W2079075723 @default.
• W2894492020 cites W2087046564 @default.
• W2894492020 cites W2099752220 @default.
• W2894492020 cites W2100945326 @default.
• W2894492020 cites W2116095691 @default.
• W2894492020 cites W2141748482 @default.
• W2894492020 cites W2152294869 @default.
• W2894492020 cites W2153867442 @default.
• W2894492020 cites W2167529385 @default.
• W2894492020 cites W2170581969 @default.
• W2894492020 cites W2237254160 @default.
• W2894492020 cites W2284518822 @default.
• W2894492020 cites W2415950182 @default.
• W2894492020 cites W2462987326 @default.
• W2894492020 cites W2587686362 @default.
• W2894492020 cites W2766126886 @default.
• W2894492020 cites W2802168781 @default.
• W2894492020 cites W4210983935 @default.
• W2894492020 doi "https://doi.org/10.1097/coc.0000000000000478" @default.
• W2894492020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30204614" @default.
• W2894492020 hasPublicationYear "2019" @default.
• W2894492020 type Work @default.
• W2894492020 sameAs 2894492020 @default.
• W2894492020 citedByCount "18" @default.
• W2894492020 countsByYear W28944920202019 @default.
• W2894492020 countsByYear W28944920202020 @default.
• W2894492020 countsByYear W28944920202021 @default.
• W2894492020 countsByYear W28944920202022 @default.
• W2894492020 countsByYear W28944920202023 @default.
• W2894492020 crossrefType "journal-article" @default.
• W2894492020 hasAuthorship W2894492020A5005319110 @default.
• W2894492020 hasAuthorship W2894492020A5038576978 @default.
• W2894492020 hasAuthorship W2894492020A5040231574 @default.
• W2894492020 hasAuthorship W2894492020A5044033864 @default.
• W2894492020 hasAuthorship W2894492020A5053179795 @default.
• W2894492020 hasAuthorship W2894492020A5057926104 @default.
• W2894492020 hasAuthorship W2894492020A5063795761 @default.
• W2894492020 hasAuthorship W2894492020A5064767706 @default.
• W2894492020 hasAuthorship W2894492020A5065945024 @default.
• W2894492020 hasAuthorship W2894492020A5066976468 @default.
• W2894492020 hasAuthorship W2894492020A5071060598 @default.
• W2894492020 hasAuthorship W2894492020A5071208029 @default.
• W2894492020 hasAuthorship W2894492020A5071855568 @default.
• W2894492020 hasAuthorship W2894492020A5081355165 @default.
• W2894492020 hasAuthorship W2894492020A5088690292 @default.
• W2894492020 hasConcept C126322002 @default.
• W2894492020 hasConcept C126894567 @default.
• W2894492020 hasConcept C141071460 @default.
• W2894492020 hasConcept C197934379 @default.
• W2894492020 hasConcept C2777472916 @default.
• W2894492020 hasConcept C2777546739 @default.
• W2894492020 hasConcept C2778560582 @default.
• W2894492020 hasConcept C2778822529 @default.
• W2894492020 hasConcept C2779134260 @default.
• W2894492020 hasConcept C2781064419 @default.
• W2894492020 hasConcept C71924100 @default.
• W2894492020 hasConcept C78795084 @default.
• W2894492020 hasConcept C90924648 @default.
• W2894492020 hasConceptScore W2894492020C126322002 @default.
• W2894492020 hasConceptScore W2894492020C126894567 @default.
• W2894492020 hasConceptScore W2894492020C141071460 @default.
• W2894492020 hasConceptScore W2894492020C197934379 @default.
• W2894492020 hasConceptScore W2894492020C2777472916 @default.
• W2894492020 hasConceptScore W2894492020C2777546739 @default.
• W2894492020 hasConceptScore W2894492020C2778560582 @default.
• W2894492020 hasConceptScore W2894492020C2778822529 @default.
• W2894492020 hasConceptScore W2894492020C2779134260 @default.
• W2894492020 hasConceptScore W2894492020C2781064419 @default.
• W2894492020 hasConceptScore W2894492020C71924100 @default.
• W2894492020 hasConceptScore W2894492020C78795084 @default.
• W2894492020 hasConceptScore W2894492020C90924648 @default.
• W2894492020 hasIssue "1" @default.
• W2894492020 hasLocation W28944920201 @default.

• next